secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2022-09-07T23:59:59+00:00
Accession:  0001787306-22-000061
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis acquires Ducentis for ~$30M upfront; DS-234 for atopic dermatitis
-------------------------------------------------------------------------

- Upfront consideration ~$30M (~$16M cash + ~$14M in stock); contingent milestones up to ~$400M.
- DS-234 is a CD200R agonist (checkpoint agonism) targeting atopic dermatitis, a large underserved market.
- Arcutis had ~$283M cash as of June 2022 plus $285M from Aug financings; deal not material to financial plans.
- Closing expected Q3 2022; no stockholder approval required; Ducentis CSO retained as consultant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730622000061/0001787306-22-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730622000061/arqt-20220907.htm
  HTML page:      https://secwatch.observer/filing/0001787306-22-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer